Bernstein Raises Price Target for CVS Health Amid Medicare Advantage Turnaround

Bernstein upgraded its price target for CVS Health (NYSE:CVS) from $94 to $106 and reiterated an Outperform rating, citing the company's strong positioning in the Medicare Advantage turnaround. The firm noted that PBM reform has reduced uncertainty around CVS' business strategy.

By Vardah Gill Fri, May 22, 2026 at 5:42 PM GMT+3 2 min read · Yahoo Finance · May 22, 2026, 14:42 UTC

Bernstein Raises Price Target for CVS Health Amid Medicare Advantage Turnaround

Tickers: $CVS

Topics: CVS Health Earnings Guidance Medicare Advantage PBM Reform

Read the full article at Yahoo Finance

More World news

EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance PR Newswire · November 12, 2026, 18:36 UTC
Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree PR Newswire · November 12, 2026, 18:36 UTC
Fed's Schmid Argues Construction Productivity is Key to Housing Affordability Over Interest Rate Cuts Seeking Alpha · November 12, 2026, 18:33 UTC
PROG Holdings Reports 59% GMV Growth and Announces $100 Million Share Repurchase Program Motley Fool · November 12, 2026, 18:30 UTC
Corteva Shares Plunge Over Q3 Earnings Miss and Pricing Pressures Motley Fool · November 12, 2026, 18:31 UTC
Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC
U.S. 30-Year Treasury Auction Yields Rise as Demand Weakens Seeking Alpha · November 12, 2026, 18:30 UTC
Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC